Torasemide

How to order Torasemide

1. Find the drug you need on our site.
2. Pick a clinic. See the price.
3. Fill in a short health form.
4. A doctor reads your form.
5. If it is safe for you, they say yes.
6. Your order ships fast to your door.
7. It comes in a plain, sealed box.

Why use us? We compare UK clinics. We show you the price and how fast they ship. We do not sell drugs. We just help you find the best one for you.

Is it safe? Yes. All our clinics are UK-based. A real doctor reads each form. They will not sell to you if it is not safe for you.

Torasemide on Prescriptsy

Torasemide is described on Prescriptsy as independent product information.

Here you can understand how online consultation works, what medical checks partner clinics carry out, and which factors matter when comparing providers.

We do not sell medicines directly, but help users compare licensed healthcare partners on price, delivery speed, service quality, and overall trustworthiness.

Torasemide is a loop diuretic prescribed in the United Kingdom for the treatment of oedema (fluid retention) associated with congestive heart failure.

It belongs to the same pharmacological class as furosemide and bumetanide but offers several pharmacokinetic advantages, including a longer duration of action, higher oral bioavailability, and a more predictable dose-response relationship.

These properties make torasemide a valuable alternative for patients who require reliable oral diuretic therapy to manage fluid overload.

Heart failure is a major public health challenge in the United Kingdom, affecting approximately 920,000 people, with around 200,000 new diagnoses each year.

It is the most common cause of hospitalisation in people over 65 and accounts for approximately 2% of total NHS expenditure.

Fluid retention, manifesting as peripheral oedema (swollen ankles and legs), pulmonary congestion (fluid on the lungs causing breathlessness), and weight gain, is one of the hallmark features of decompensated heart failure.

Diuretics are a cornerstone of heart failure management, providing symptomatic relief by reducing fluid overload.

This page provides comprehensive clinical information about torasemide, including how it works, dosing guidance, side effects, safety warnings, and how to obtain a prescription in the UK.

Important safety information about torasemide

Before reading further, note the following key safety points about torasemide.

• Do not take torasemide if you are severely dehydrated, have no urine output, or have uncorrected severe electrolyte disturbances.
• Regular blood tests for potassium, sodium, magnesium, and kidney function are essential during treatment.
• Weigh yourself daily and report sudden weight gains of more than 2 kg in 2 to 3 days to your GP or heart failure nurse.
• Rise slowly from sitting or lying positions to reduce the risk of dizziness or fainting.
• Take your dose in the morning to avoid waking at night to urinate.

What is congestive heart failure

Heart failure is a clinical syndrome in which the heart is unable to pump blood efficiently enough to meet the body's metabolic demands.

It can result from damage to the heart muscle (commonly caused by coronary artery disease or myocardial infarction), prolonged high blood pressure (hypertension), valvular heart disease, cardiomyopathy, or arrhythmias.

The term "congestive" heart failure refers to the build-up of fluid (congestion) that occurs when the weakened heart cannot pump blood forward effectively, causing fluid to back up into the lungs (left-sided heart failure) or the peripheral tissues (right-sided heart failure) or both.

Symptoms of heart failure include breathlessness (initially on exertion, later at rest), orthopnoea (breathlessness when lying flat), paroxysmal nocturnal dyspnoea (waking suddenly at night gasping for breath), peripheral oedema (swollen ankles, legs, and sometimes abdomen), fatigue, and reduced exercise tolerance.

The New York Heart Association (NYHA) functional classification grades heart failure severity from Class I (no limitation of physical activity) to Class IV (symptoms at rest).

Heart failure in the United Kingdom

Heart failure affects approximately 2% of the adult population in the UK, rising to 10 to 15% in people over 70.

It accounts for over 80,000 hospital admissions per year in England alone. The 5-year survival rate after diagnosis is approximately 50%, comparable to many common cancers.

NICE Guideline NG106 (Chronic heart failure in adults: diagnosis and management) provides the framework for evidence-based management in the UK, emphasising the importance of appropriate pharmacotherapy, lifestyle modification, and specialist multidisciplinary care.

How torasemide works: mechanism of action

Torasemide acts on the thick ascending limb of the loop of Henle in the nephron, the functional unit of the kidney.

Here, it inhibits the sodium-potassium-2 chloride cotransporter (NKCC2, also known as the Na-K-2Cl symporter) on the luminal (urine-facing) membrane of tubular epithelial cells.

This transporter is responsible for reabsorbing approximately 25% of filtered sodium from the tubular fluid back into the blood.

By blocking this transporter, torasemide prevents the reabsorption of sodium, potassium, and chloride, which are then excreted in the urine along with water that follows osmotically.

The result is a potent diuresis (increased urine production) and natriuresis (increased sodium excretion), which reduces total body fluid volume and relieves the symptoms of congestion.

Pharmacokinetic advantages over furosemide

Torasemide has several pharmacokinetic properties that distinguish it from furosemide, the most commonly prescribed loop diuretic.

Its oral bioavailability is approximately 80 to 90%, compared with 40 to 60% for furosemide.

This higher and more consistent absorption means that the dose-response relationship is more predictable, and the effectiveness of the oral formulation more closely matches that of intravenous administration.

The absorption of furosemide, by contrast, is variable and can be further impaired by gut oedema in patients with decompensated heart failure, leading to diuretic resistance.

Torasemide has a longer elimination half-life (3 to 4 hours versus 1 to 2 hours for furosemide), which translates to a longer duration of diuretic action (6 to 8 hours versus 4 to 6 hours).

This produces a more gradual and sustained diuretic effect, which may be better tolerated than the rapid, intense diuresis associated with furosemide.

Some patients report less urgency and fewer episodes of incontinence with torasemide.

Torasemide also has mild anti-aldosterone properties, which may result in slightly lower urinary potassium losses compared with equidiuretic doses of furosemide. This could be advantageous in heart failure patients who are already at risk of hypokalaemia from multiple medications.

Clinical evidence and national guidelines

The TORIC study (Torasemide In Congestive heart failure) was a large post-marketing surveillance study comparing torasemide with furosemide in over 1,300 patients with NYHA Class II to III heart failure.

Patients treated with torasemide showed a significantly lower rate of the combined endpoint of all-cause mortality and hospitalisation for heart failure compared with furosemide.

The torasemide group also had significantly fewer hypokalaemia events.

While the TORIC study was not randomised, its findings contributed to growing interest in torasemide as an alternative to furosemide in heart failure.

More recently, the TRANSFORM-HF trial (Torsemide Comparison With Furosemide for Management of Heart Failure) was a randomised, open-label trial comparing torasemide with furosemide in over 2,800 patients hospitalised for heart failure.

The primary endpoint of all-cause mortality at 12 months did not differ significantly between the two groups, suggesting that torasemide and furosemide are broadly equivalent in terms of hard clinical outcomes.

However, the trial confirmed the favourable pharmacokinetic profile of torasemide, and clinical experience suggests that some patients who respond poorly to oral furosemide (due to variable absorption) may benefit from switching to torasemide.

NICE NG106 recommends diuretics for the relief of congestive symptoms and fluid retention in heart failure.

While it does not preferentially recommend one loop diuretic over another, it acknowledges that the choice should be guided by clinical response, tolerability, and patient preference.

The BNF lists torasemide alongside furosemide and bumetanide as options for the treatment of oedema in heart failure.

Dosage and administration

Torasemide is available as tablets for oral administration. The dose is individualised based on the severity of fluid retention and the patient's response to treatment.

Starting and maintenance doses

The usual starting dose for oedema associated with congestive heart failure is 5 mg once daily in the morning.

If the diuretic response is insufficient (assessed by monitoring body weight, peripheral oedema, breathlessness, and urine output), the dose may be increased to 10 mg once daily, and if necessary to a maximum of 20 mg once daily.

Most patients are maintained on 5 to 10 mg per day.

Switching from furosemide

The approximate dose equivalence between furosemide and torasemide varies in the literature but is generally cited as furosemide 40 mg being approximately equivalent to torasemide 10 to 20 mg.

This is a guideline only; individual dose adjustment based on clinical response is always required.

Patients switching from furosemide to torasemide should have their weight, symptoms, blood pressure, and renal function monitored closely during the transition period.

Special populations

Elderly patients do not require initial dose adjustment but should be monitored carefully for dehydration, hypotension, and electrolyte disturbances.

In hepatic cirrhosis with ascites, start at the lowest dose (2.5 to 5 mg daily) with close electrolyte monitoring, as rapid diuresis can precipitate hepatic encephalopathy.

In renal impairment, torasemide retains efficacy even when the glomerular filtration rate is significantly reduced, making it preferable to thiazide diuretics in this setting.

Higher doses may be required to achieve the desired diuretic effect.

Side effects of torasemide

Electrolyte and metabolic effects

The most clinically important side effects of torasemide are electrolyte disturbances. Hypokalaemia is common and may cause muscle weakness, cramps, palpitations, and cardiac arrhythmias.

It is particularly dangerous in patients taking digoxin, as hypokalaemia potentiates digoxin toxicity. Hyponatraemia (low sodium) can cause confusion, nausea, and seizures.

Hypomagnesaemia may develop with chronic use and can exacerbate hypokalaemia. Hypochloraemic metabolic alkalosis may occur with prolonged high-dose therapy.

Regular blood test monitoring is essential to detect and correct these disturbances.

Potassium supplementation or the addition of a potassium-sparing diuretic (such as spironolactone, which is also independently indicated in heart failure) may be required.

Volume depletion

Excessive diuresis can lead to dehydration and hypotension, manifesting as dizziness, lightheadedness, dry mouth, thirst, and reduced urine output.

Orthostatic hypotension (a drop in blood pressure on standing) is particularly common in elderly patients and can increase the risk of falls.

Patients should be advised to rise slowly from seated or lying positions and to report persistent dizziness to their clinical team.

Renal effects

Transient increases in blood urea and creatinine may occur during diuretic therapy, reflecting reduced renal perfusion from volume depletion. This is usually reversible with dose reduction.

In patients with pre-existing renal impairment, close monitoring of renal function is essential. Hyperuricaemia (elevated uric acid) may occur and can precipitate gout in predisposed individuals.

Other effects

Headache, dizziness, and gastrointestinal symptoms (nausea, diarrhoea, constipation) are reported. Hyperglycaemia may occur in diabetic patients, requiring closer blood glucose monitoring and possible adjustment of diabetic medication.

Ototoxicity (hearing disturbance, tinnitus) is a rare class effect of loop diuretics, more commonly associated with high intravenous doses or concurrent use of other ototoxic drugs.

Photosensitivity skin reactions have been reported uncommonly.

When to seek medical advice

Contact your GP, heart failure nurse, or NHS 111 if you experience persistent muscle cramps or weakness (possible low potassium), dizziness or fainting (possible dehydration or low blood pressure), sudden weight gain (possible worsening heart failure), reduced urine output, or confusion.

Report any suspected adverse reactions via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk .

Warnings and precautions

Contraindications

Torasemide must not be used in patients with anuria, severe hypovolaemia, severe hypokalaemia, severe hyponatraemia, or known hypersensitivity to torasemide or any excipient. It should not be used in patients with hepatic coma or pre-coma.

Electrolyte monitoring

Serum potassium, sodium, magnesium, chloride, and bicarbonate should be monitored before starting treatment, during dose titration (typically weekly), and at regular intervals during maintenance therapy.

Renal function (creatinine and urea) and blood pressure should be monitored concurrently.

Patients taking digoxin require particularly careful potassium monitoring, as hypokalaemia greatly increases the risk of digoxin-related cardiac arrhythmias.

Drug interactions

Torasemide potentiates the blood pressure-lowering effects of other antihypertensive agents, including ACE inhibitors, angiotensin receptor blockers, beta-blockers, and calcium channel blockers.

First-dose hypotension may occur when starting an ACE inhibitor in a patient already taking torasemide; the diuretic dose may need temporary reduction.

NSAIDs reduce the diuretic and antihypertensive effects of torasemide and may worsen renal function. Aminoglycoside antibiotics have additive ototoxic and nephrotoxic effects.

Lithium clearance is reduced by loop diuretics, potentially leading to lithium toxicity. Corticosteroids increase the risk of hypokalaemia when used concurrently.

Pregnancy and breastfeeding

Torasemide should be used during pregnancy only when clearly necessary and the benefit outweighs the risk.

Loop diuretics cross the placenta and may affect fetal electrolyte balance and renal function. They are not recommended for the management of physiological oedema of pregnancy.

It is unknown whether torasemide is excreted in breast milk. If treatment is essential, breastfeeding should be discontinued.

How to get a torasemide prescription in the UK

Torasemide is a prescription-only medicine (POM) in the UK. It is typically prescribed by GPs, cardiologists, or heart failure specialist nurses.

Most patients are started on torasemide either in hospital during an admission for decompensated heart failure or in the community by their GP or heart failure team following appropriate assessment.

Repeat prescriptions are managed through the patient's GP surgery. All UK prescriptions are dispensed by registered pharmacies.

The standard NHS prescription charge in England is 9.90 pounds per item; prescriptions are free in Scotland, Wales, and Northern Ireland.

Living with heart failure: practical self-management

Taking torasemide as prescribed is an important part of managing heart failure, but comprehensive self-management involves several additional strategies.

Monitor your weight daily and record it in a diary or app; sudden weight gain may indicate fluid retention before symptoms become apparent.

Restrict your fluid intake as advised by your clinical team (typically 1.5 to 2 litres per day, though this varies).

Reduce dietary sodium intake, as excess salt promotes fluid retention.

Aim for no more than 6 g of salt per day, and be aware that processed foods, ready meals, and takeaway foods are often high in hidden salt.

Stay as physically active as your condition allows. Exercise-based cardiac rehabilitation improves fitness, quality of life, and survival in heart failure patients and is recommended by NICE.

Take all prescribed heart failure medications consistently, including ACE inhibitors (or ARBs), beta-blockers, and mineralocorticoid receptor antagonists (such as spironolactone or eplerenone), which have proven mortality and morbidity benefits.

Attend regular heart failure reviews with your GP, practice nurse, or heart failure specialist nurse.

When to seek urgent medical advice

Heart failure symptoms can deteriorate rapidly and sometimes require emergency medical attention.

Call 999 or attend A&E if you experience severe breathlessness at rest or when lying flat, chest pain (which may indicate a heart attack or angina), fainting or collapse, rapid or irregular heartbeat with breathlessness or chest pain, or confusion and drowsiness (which may indicate electrolyte disturbance or cardiogenic shock).

Contact your GP or heart failure nurse urgently if you gain more than 2 kg in 2 to 3 days, develop new or worsening ankle swelling, notice increasing breathlessness on exertion, or are unable to sleep flat due to breathlessness.

Early intervention during deterioration can often prevent hospital admission.

Sources

• Torasemide, Summary of Product Characteristics (EMC)
• Torasemide, British National Formulary (BNF)
• NICE NG106: Chronic heart failure in adults
• Heart failure, NHS
• Heart failure, British Heart Foundation
• MHRA Yellow Card Scheme